

# ASX Release

---

## SUDA LTD ATTENDING TWO KEY PARTNERING EVENTS

- Attending the AusBiotech National Conference, 29-31 October 2014 on the Gold Coast, Queensland
- Attending the BIO-Europe International Partnering Conference, 3-5 November 2014 in Frankfurt, Germany
- Meetings scheduled with approximately 40 international pharmaceutical companies
- Interest from the industry spans SUDA's pipeline and OroMist drug delivery technology

**PERTH, AUSTRALIA – 29 October 2014:** SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has scheduled meetings with approximately 40 international pharmaceutical companies over the next two weeks at two key business development conferences.

Following on from its successful industry outreach initiative, which commenced in March 2014, SUDA's business development team, led by the Company's Chief Business Officer, Mr Nick Woolf, will be attending the AusBiotech National Conference, being held 29-31 October 2014 on the Gold Coast in Queensland; and the BIO-Europe International Partnering Conference, taking place 3-5 November 2014 in Frankfurt, Germany. These events bring together industry leaders from across the globe and offer pre-eminent opportunities to meet with prospective licensees, acquirers and collaborators within the pharmaceutical industry.

The interest from pharmaceutical companies spans all of the Company's clinical-stage oral sprays, as well as the application of SUDA's OroMist drug delivery technology to new drugs. Approximately half of the meetings are continuing the ongoing discussions with companies that SUDA has been in dialogue with since its initial business development outreach in March 2014.

Commenting on SUDA's business development activities, Mr Nick Woolf, Chief Business Officer of SUDA said: "This is an exciting and busy period for SUDA's business development team. We have active discussions with over 30 pharmaceutical companies and are working hard to finalise deals over the coming weeks and months. The AusBiotech and BIO-Europe events provide great forums for us to have face-to-face meetings with some of our existing prospective partners, as well providing an opportunity to meet with other pharmaceutical companies that are interested in our pipeline and OroMist drug delivery technology."



**Further information:**

**STEPHEN CARTER**

**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**

**SUDA LTD**

Tel: +61 8 6142 5555

[sjcarter@sudaltd.com.au](mailto:sjcarter@sudaltd.com.au)

**NOTES TO EDITORS:**

**About SUDA LTD**

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's most advanced product is a novel sub-lingual treatment, ArTiMist™, for severe malaria in children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other development stage products include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting and erectile dysfunction. For more information, visit [www.sudaltd.com.au](http://www.sudaltd.com.au)